Brief: SAB Biotherapeutics Provides Company Update For Q1 2023 Financial Results

SAB Biotherapeutics

16/05/2023 14:29

May 16 (Reuters) - SAB Biotherapeutics Inc  SABS.O :
    * SAB BIOTHERAPEUTICS PROVIDES COMPANY UPDATE FOR Q1 2023
FINANCIAL RESULTS
    * SAB BIOTHERAPEUTICS INC - QTRLY  LOSS PER SHARE $0.15
    * SAB BIOTHERAPEUTICS INC - CASH AND CASH EQUIVALENTS WERE
$13.1
MILLION AS OF MARCH 31, 2023
    * SAB BIOTHERAPEUTICS - EXPECTS EXISTING BUSINESS PLAN,
CASH, CASH
EQUIVALENTS TO BE SUFFICIENT TO FUND OPERATING EXPENSES, CAPEX
REQUIREMENTS THROUGH DEC 2023

Source text for Eikon:  ID:nGNXb7Z3wW 
Further company coverage:  SABS.O 

 ((Reuters.Brief@thomsonreuters.com;))